China Seen Benefiting From U.S. FDA Ban On 30 Ranbaxy Drugs
This article was originally published in PharmAsia News
Executive Summary
China could be the main beneficiary of the U.S. ban on 30 Ranbaxy Laboratories drugs, say analysts in China. One said Chinese drug makers are in line to take the market sector in the United States that Ranbaxy could lose by the ban. Pharmas in China have been increasing their own production, and the country's regulatory requirements are expected to help Chinese pharmaceuticals gain a share of India's U.S. market. Another notes China's leadership in making active pharmaceutical ingredients used by most drug makers. (Click here for more